TFEB Inhibitors
TFEB inhibitors constitute a distinctive class of compounds capable of influencing TFEB activity through direct or indirect modulation of specific signaling pathways and cellular processes. Among them, Bafilomycin A1 and Concanamycin A, both V-ATPase inhibitors, exert their effects by disrupting lysosomal acidification. Lysosomal pH plays a pivotal role in TFEB regulation, and these inhibitors indirectly impact TFEB by interfering with lysosomal processes, ultimately influencing TFEB translocation. Lysosomotropic agents, such as Chloroquine and NH4Cl, introduce alterations in lysosomal conditions by elevating lysosomal pH. This adjustment impacts TFEB translocation, as TFEB is highly responsive to changes in lysosomal environments. These agents indirectly modulate TFEB by influencing lysosomal function, highlighting the intricate connection between lysosomal dynamics and TFEB activity.
GSK-3 Inhibitor IX, SB216763, and U0126 operate by modulating the Wnt and MAPK pathways, respectively, indirectly affecting TFEB activity. TFEB intricately connects with these signaling pathways, and these inhibitors exert their effects by influencing the activity of Wnt and MAPK networks. Understanding the interplay between TFEB and these pathways provides insight into the indirect modulation of TFEB by these inhibitors. Protease and proteasome inhibitors, Leupeptin and MG-132, respectively, impact TFEB indirectly by altering lysosomal proteolysis and degradation pathways. TFEB activity is intricately regulated by these processes, and these inhibitors interfere with protein turnover, indirectly modulating TFEB. This showcases the diverse mechanisms through which TFEB inhibitors can influence cellular processes connected with TFEB regulation. Rapamycin and Torin 1, both mTOR inhibitors, activate TFEB indirectly by inhibiting mTOR, a negative regulator of TFEB. These inhibitors disrupt the mTOR-dependent regulatory pathway, leading to increased TFEB activity and nuclear translocation. The indirect modulation of TFEB by these mTOR inhibitors demonstrates the pivotal role of mTOR in governing TFEB activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
V-ATPase inhibitor. Bafilomycin A1 disrupts lysosomal acidification by inhibiting V-ATPase, indirectly affecting TFEB translocation to the nucleus. Lysosomal pH is crucial for the activation of mTORC1, a negative regulator of TFEB, making Bafilomycin A1 an indirect inhibitor of TFEB activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Lysosomotropic agent. Chloroquine accumulates in lysosomes, raising their pH and disrupting TFEB translocation. By altering lysosomal conditions, Chloroquine indirectly modulates TFEB activity, as TFEB is sensitive to lysosomal calcium levels and pH. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
V-ATPase inhibitor. Concanamycin A, similar to Bafilomycin A1, disrupts lysosomal acidification by inhibiting V-ATPase. This inhibition indirectly impacts TFEB translocation by interfering with lysosomal function, a critical factor in the regulation of TFEB activity. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
Glycogen synthase kinase 3 (GSK-3) inhibitor. GSK-3 Inhibitor IX modulates the Wnt pathway, influencing TFEB indirectly as Wnt signaling is linked to TFEB expression and activity. GSK-3 Inhibitor IX indirectly modulates TFEB by affecting the activity of the Wnt pathway, which intersects with TFEB regulatory networks. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Protease inhibitor. Leupeptin inhibits lysosomal proteases, indirectly impacting TFEB activity as the regulation of lysosomal proteolysis is interconnected with TFEB translocation and function. By interfering with lysosomal processes, Leupeptin serves as an indirect modulator of TFEB activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor. MG-132 inhibits the proteasome, indirectly influencing TFEB degradation. TFEB is regulated by proteasomal degradation, and inhibition of the proteasome by MG-132 leads to TFEB accumulation, indirectly modulating its activity in cellular processes. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
Lysosomotropic agent. NH4Cl raises lysosomal pH, affecting lysosomal function and TFEB translocation. By altering lysosomal conditions, NH4Cl indirectly modulates TFEB activity as TFEB is sensitive to changes in lysosomal pH. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
GSK-3 inhibitor. SB216763 modulates the Wnt pathway by inhibiting GSK-3, indirectly influencing TFEB activity as Wnt signaling intersects with TFEB regulatory networks. SB216763 indirectly modulates TFEB by affecting the activity of the Wnt pathway, impacting TFEB expression and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3-kinase inhibitor. Wortmannin modulates the PI3-kinase/Akt pathway, indirectly influencing TFEB activity as PI3-kinase signaling intersects with TFEB regulatory networks. Wortmannin indirectly modulates TFEB by affecting the activity of the PI3-kinase/Akt pathway, impacting TFEB expression and function. | ||||||